KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2025)

Alnylam Pharmaceuticals' Current Leases history spans 7 years, with the latest figure at $45.5 million for Q4 2025.

  • For Q4 2025, Current Leases rose 8.67% year-over-year to $45.5 million; the TTM value through Dec 2025 reached $45.5 million, up 8.67%, while the annual FY2025 figure was $45.5 million, 8.67% up from the prior year.
  • Current Leases reached $45.5 million in Q4 2025 per ALNY's latest filing, up from $44.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $46.1 million in Q2 2025 to a low of $38.9 million in Q1 2021.
  • Average Current Leases over 5 years is $42.2 million, with a median of $41.7 million recorded in 2024.
  • Peak YoY movement for Current Leases: skyrocketed 34.0% in 2021, then decreased 3.21% in 2024.
  • A 5-year view of Current Leases shows it stood at $40.5 million in 2021, then grew by 3.5% to $42.0 million in 2022, then decreased by 1.09% to $41.5 million in 2023, then increased by 0.91% to $41.9 million in 2024, then increased by 8.67% to $45.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Current Leases are $45.5 million (Q4 2025), $44.8 million (Q3 2025), and $46.1 million (Q2 2025).